Supremes quash Stanford patent suit; Actelion adds a COO; Investigators stumped by lethal E. coli;

@FierceBiotech: Experimental oral contraceptive looks promising for men. Story | Follow @FierceBiotech

@JohnCFierce: Sanofi ran a sub-group analysis on iniparib on the Ph3 failure and found 10.8 overall survival vs 8.1 month on chemo. News | Follow @JohnCFierce  

> The U.S. Supreme Court has dealt a final blow to Stanford University's lawsuit against a unit of Roche, limiting the patent rights of universities heavily engaged in research work. Story

> Now that Actelion has successfully beaten back a coup attempt by one of its biggest investors, it can go ahead and institute one of the rebel group's suggested reforms. Europe's biggest biotech has appointed a COO in a management shakeup intended to give the CEO more time for strategic planning. Report

> Bethesda, MD-based Northwest Biotherapeutics has arranged for $28 million in new funding. Release

> Emergent BioSolutions has acquired the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas, from TenX BioPharma. Emergent release

Pharma News

@FiercePharma: Once-feared prosecutor now defends firms. Report | Follow @FiercePharma

> Will Novartis follow through with Gen-Probe bid? Report

> U.K. accuses Servier of generic-blocking, sues for £220M. Article

> AstraZeneca wraps up pay-discrimination suit for $250K. Story

Biotech Research News

> Anti-pain peptide a possible alternative to addictive opioids. Item 

> OCD appears to be genetic, but hoarding likely environmental. Article

> Nail-fungus drug also helps prostate cancer patients. Report 

> Obesity vaccine would suppress hunger hormone. Story 

Manufacturing News

> Impax reveals warning letter related to drug recall. News

> Chinese plant spews toxins into air, water. Report 

> FDA steps in to prevent drug shortages. Article

> Alli counterfeiter gets 87 months. Item

> Cargo theft hype masks pharma containment efforts. News

And Finally...The infection rate linked to a lethal new strain of E. coli has slowed, but investigators still don't know how it is spread. Story